PanGen Biotech Inc. (KOSDAQ:222110)

PanGen Biotech Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	3,007	3,756	1,430	45.4	838.28	8,901
Short-Term Investments	9,044	10,048	10,002	149.24	2	15,199
Cash & Short-Term Investments	12,052	13,804	11,432	194.64	840.28	24,100
Cash Growth	-29.31%	20.74%	5773.48%	-76.84%	-96.51%	28.95%
Accounts Receivable	3,077	1,574	2,959	2,208	689.81	1,089
Other Receivables	135.86	116.77	51.8	8.54	221.29	241.03
Receivables	3,212	1,690	3,261	2,330	974.1	1,393
Inventory	8,247	7,240	6,001	6,925	6,630	4,373
Prepaid Expenses	47.96	20.7	53.96	58.91	71.41	21.39
Other Current Assets	241.27	385.81	20.35	333.62	60.91	1,267
Total Current Assets	23,800	23,140	20,768	9,843	8,576	31,154
Property, Plant & Equipment	6,207	5,986	5,805	6,240	6,608	6,748
Long-Term Investments	-0	0	0	0	0	-0
Other Intangible Assets	1,141	1,065	785.13	879.93	269.63	313.41
Long-Term Deferred Charges	1,639	1,967	2,622	3,278	3,933	4,589
Other Long-Term Assets	490.37	542.29	564.14	501.5	1,287	473.47
Total Assets	33,278	32,700	30,545	20,741	20,674	43,277

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	341.94	157.84	423.33	298.82	255.48	381.91
Accrued Expenses	200.85	186.02	-	-	-	-
Short-Term Debt	-	962.05	816.3	2,014	-	18,692
Current Portion of Leases	1.3	0.39	1.84	1.69	1.56	1.43
Other Current Liabilities	1,948	1,440	1,657	3,396	872.49	811.14
Total Current Liabilities	2,492	2,746	2,899	5,711	1,130	19,886
Long-Term Leases	6.09	-	0.39	2.24	3.93	5.49
Pension & Post-Retirement Benefits	-	-	2,707	2,432	2,114	2,171
Other Long-Term Liabilities	30	30	30	30	206.41	116.22
Total Liabilities	2,528	2,776	5,636	8,175	3,454	22,179

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	6,757	6,747	6,449	5,339	5,339	5,336
Additional Paid-In Capital	10,892	10,779	67,712	57,402	57,402	57,371
Retained Earnings	12,400	11,697	-49,953	-50,876	-46,210	-42,062
Comprehensive Income & Other	700.82	700.82	700.82	700.82	688.64	452.86
Total Common Equity	30,750	29,924	24,909	12,566	17,219	21,098
Shareholders' Equity	30,750	29,924	24,909	12,566	17,219	21,098
Total Liabilities & Equity	33,278	32,700	30,545	20,741	20,674	43,277

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	7.39	962.44	818.54	2,018	5.49	18,699
Net Cash (Debt)	12,044	12,841	10,614	-1,823	834.79	5,402
Net Cash Growth	-25.47%	20.99%	-	-	-84.55%	1760.05%
Net Cash Per Share	886.83	953.30	922.27	-170.60	78.21	528.69
Filing Date Shares Outstanding	16.07	13.49	12.9	10.68	10.68	10.67
Total Common Shares Outstanding	16.07	13.49	12.9	10.68	10.68	10.67
Working Capital	21,308	20,394	17,869	4,132	7,447	11,267
Book Value Per Share	1914.07	2217.56	1931.18	1176.85	1612.67	1976.95
Tangible Book Value	29,608	28,859	24,124	11,686	16,950	20,784
Tangible Book Value Per Share	1843.02	2138.62	1870.31	1094.44	1587.42	1947.58
Land	1,174	1,174	1,174	1,174	1,174	1,174
Buildings	3,909	3,909	3,909	3,909	3,909	3,909
Machinery	12,844	12,382	11,766	11,545	11,434	10,381
Construction In Progress	-	112.7	-	125.36	-	332.66

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 4, 2026

Data Sources Report a data error